Gene to Structure Strategic opportunity to cross-sell integrated gene-to-structure workflows that combine protein production with cryo-EM structure determination, accelerating drug discovery timelines for mid to late-stage biopharma and biotech clients.

Scale and Specialization NIS claims North America’s largest cryo-EM footprint and specialists, presenting a compelling value prop for large projects or repeat work from pharma sponsors requiring high-throughput, high-quality imaging and single-particle analysis.

New Capabilities Acquisition of Proteos expands offerings into complete gene-to-structure workflows and standalone recombinant protein production, enabling target customers to consolidate service providers and reduce handoffs.

Growth Funding Recent Series B1 funding and leadership appointments indicate strong growth trajectory and financial backing, signaling readiness to scale partnerships, capacity, and service levels for enterprise customers.

Collaborative Ecosystem Active partnerships in the LNP and protein production space suggest opportunities to co-develop or bundle services with adjacent players, attracting biotech and biotech-focused CDMOs seeking integrated imaging and formulation support.